We are live on ! Find out more
ATRC icon

AtriCure

233 hedge funds and large institutions have $1.93B invested in AtriCure in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 90 increasing their positions, 74 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

72% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $747K

64% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 22

22% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 74

14% more capital invested

Capital invested by funds: $1.7B → $1.93B (+$231M)

4% more funds holding

Funds holding: 223233 (+10)

1.11% more ownership

Funds ownership: 96.88%97.99% (+1.1%)

Holders
233
Holders Change
+10
Holders Change %
+4.48%
% of All Funds
2.82%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
36
Increased
90
Reduced
74
Closed
22
Calls
$1.29M
Puts
$747K
Net Calls
+$539K
Net Calls Change
-$983K

ATRC Hedge Fund Activity: Q4 2025 in Review

233 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q4 2025, worth a combined $1.93B — up 14% from $1.7B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ATRC positions and 22 closed out — a net gain of 14 holders — while 90 added to existing stakes and 74 trimmed.

The largest buyer was Marshall Wace, adding an estimated $13M. The largest seller was Macquarie Group, exiting entirely with an estimated $80.7M sold.

  • 233 institutional investors held AtriCure (ATRC) as of Q4 2025, up from 223 in Q3 2025.
  • Funds reported $1.93B of AtriCure stock for Q4 2025, up 14% quarter-over-quarter.
  • 36 funds opened new AtriCure positions in Q4 2025 and 22 closed out, a net change of +14 holders.
  • The largest AtriCure buyer in Q4 2025 was Marshall Wace, an estimated $13M added.
  • The largest AtriCure seller in Q4 2025 was Macquarie Group, an estimated $80.7M sold.

Based on aggregated 13F filings for Q4 2025.